Aseem Chhabra watched some great films and some huge disappointments in 2021.
This recognition is a testimony of India's strong belief in promoting entrepreneurship
In the US, the ratio of the CEO to average worker pay ratio was 373:1 in 2014.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
Currently, the investor and his family's net worth in listed firms stands at Rs 8,517 crore, compared to Rs 8,388 crore as of March 31, 2020.
The turmoil on the Street and a continued fall of the rupee may affect growth stocks, pushing equity investors back to the relative safety of defensive counters, or forcing them to flee markets, or both.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
Rosier year-end seen for Indian pharma thanks to faster US approvals.
Who do you think can be cast in the desi version of Harry Potter?
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
In its report 'Global Top Picks', Barclays expects the current bull market in global equities to continue, generating a total return of 9 per cent in 2015.
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
Pharma was the top losing index amid worries about their earnings outlook with Lupin down over 4%
Participants will watch out for the Brexit poll outcome in the late morning trades tomorrow.
With an m-cap of Rs 31,744 crore, IRCTC stood at 96th position in the overall market capitalisation ranking, the BSE data shows.
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
Indian auto and pharma industries import several critical components and raw materials from China.
This helps consumers check the authenticity of drugs simply by sending SMSes.
A record net inflow in Indian equities in the financial year ending March 2013 helped foreign investors widen their grip.
In the last one month, Indian pharmaceutical company Lupin has won US Food and Drug Administration nod for three of its contraceptive pills, and has at least nine approvals pending with the regulator.
The ace investor has gone ahead and selectively raised stake in some of these.
Regulator says fee would enable it to quicken approval process.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
Companies such as Dr Reddy's Laboratories, Sun Pharmaceutical, Lupin and Ranbaxy striving to capitalise on opportunities created by pro-generic health care reforms in the US market are facing pricing pressure as the health care supply chain is undergoing consolidation.
The list acknowledges the 'inroads women are making in the business world'.
The brokerage said it expected corporate earnings to turn around.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
This move could cost $299 million a year for Indian pharma players.
The broader Nifty closed higher by 7.30 points
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
India offices of MNCs like DHL, Google and Marriott ranked among the top workplaces in Asia.
Samina Vaziralli, daughter of joint Managing Director M K Hamied, was inducted into the company management. Cipla joins the league of major companies such as Lupin, Wockhardt, Elder Pharma, Piramal Healthcare and JB Chemicals in this regard.
Indian pharmaceutical companies, which always wanted a big share in the global copycat drug market, are betting high on the oral contraceptive (OC) market in America.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Sun Pharma stock has appreciated at 35% a year for 20 years
The anti-depressant drug market in the US is primarily ruled by Effexor XR (Venlafaxine) of Wyeth (now owned by Pfizer).
Companies which have been dropped from the list include Tata Motors, Hindustan Unilever, MRF, Glaxo SmithKline Consumer Healthcare, Pfizer, Dr Reddy's Labs, Glenmark Pharmaceuticals, HDFC and Kotak Mahindra Bank
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances